| 2022-12-31 | Gilead Sciences, Inc. | $159,041 | Grant | Cash or cash equivalent | | | 2022 |
| 2022-12-31 | Stryker Corporation | $449 | Debt forgiveness | Cash or cash equivalent | | | 2022 |
| 2022-12-22 | Abbott Laboratories | $950 | Consulting Fee | Cash or cash equivalent | ALLURE Device, Cardiac Rhythm Management | | 2022 |
| 2022-12-21 | Gilead Sciences, Inc. | $1,404 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2022 |
| 2022-12-12 | SANOFI US SERVICES INC. | $1,500 | Research payment | Cash or cash equivalent | | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2022 |
| 2022-12-05 | SANOFI US SERVICES INC. | $1,500 | Research payment | Cash or cash equivalent | | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2022 |
| 2022-12-01 | Volta Medical Inc | $3,457 | Research payment | Cash or cash equivalent | VX1 Device, CARDIOVASCULAR | Tailored AF | 2022 |
| 2022-11-14 | SANOFI US SERVICES INC. | $2,500 | Research payment | Cash or cash equivalent | | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2022 |
| 2022-10-31 | Aesculap, Inc. | $2,497 | Debt forgiveness | Cash or cash equivalent | | | 2022 |
| 2022-10-18 | Volta Medical Inc | $7,391 | Research payment | Cash or cash equivalent | VX1 Device, CARDIOVASCULAR | Tailored AF | 2022 |
| 2022-09-21 | Gilead Sciences, Inc. | $1,202 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2022 |
| 2022-09-06 | SANOFI US SERVICES INC. | $15,000 | Research payment | Cash or cash equivalent | | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab | 2022 |
| 2022-08-09 | Boston Scientific Corporation | $10,000 | Research payment | Cash or cash equivalent | GENERAL - THERAPIES Device, THERAPIES | Cardiovascular Implantable Electronic Device Data to Identify Early Indicators of COVID19 Infection and to Predict Patte | 2022 |
| 2022-08-03 | Gilead Sciences, Inc. | $13,180 | Research payment | Cash or cash equivalent | | A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhib | 2022 |
| 2022-08-01 | Gilead Sciences, Inc. | $11,375 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2022 |
| 2022-07-20 | Gilead Sciences, Inc. | $7,575 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2022 |
| 2022-07-20 | Gilead Sciences, Inc. | $1,404 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2022 |
| 2022-07-07 | Novartis Pharmaceuticals Corporation | $60,027 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ARNI WITH ARB GIVEN FOLLOWING STABILIZATION IN DECOMPENSATED HFPEF (PARAGLIDE-HFPEF) | 2022 |
| 2022-06-22 | Volta Medical Inc | $4,400 | Research payment | Cash or cash equivalent | VX1 Device, CARDIOVASCULAR | Tailored AF | 2022 |
| 2022-06-21 | Volta Medical Inc | $4,185 | Research payment | Cash or cash equivalent | VX1 Device, CARDIOVASCULAR | Tailored AF | 2022 |
| 2022-05-02 | Boston Scientific Corporation | $164 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CRM | LUX TRENDS | 2022 |
| 2022-04-18 | Novocure Inc. | $13,855 | Research payment | Cash or cash equivalent | | EF-24 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields) concurrent with standard of care therapi | 2022 |
| 2022-04-12 | BIOTRONIK INC. | $400 | Consulting Fee | Cash or cash equivalent | Edora 8 DR-T Device, Cardiology/Vascular Diseases | | 2022 |
| 2022-04-06 | Boston Scientific Corporation | $1,840 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CRM | LUX TRENDS | 2022 |
| 2022-04-06 | Boston Scientific Corporation | $517 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CRM | LUX TRENDS | 2022 |
| 2022-04-06 | Boston Scientific Corporation | $407 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CRM | LUX TRENDS | 2022 |
| 2022-04-06 | Boston Scientific Corporation | $245 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CRM | LUX TRENDS | 2022 |
| 2022-04-06 | Boston Scientific Corporation | $62 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CRM | LUX TRENDS | 2022 |
| 2022-03-31 | BIOTRONIK INC. | $2,624 | Debt forgiveness | Cash or cash equivalent | | | 2022 |
| 2022-03-21 | Boston Scientific Corporation | $10,250 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LUX TRENDS | 2022 |
| 2022-03-21 | Boston Scientific Corporation | $1,500 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCT | LUX TRENDS | 2022 |
| 2022-03-18 | Volta Medical Inc | $1,215 | Research payment | Cash or cash equivalent | VX1 Device, CARDIOVASCULAR | Tailored AF | 2022 |
| 2022-03-02 | Novartis Pharmaceuticals Corporation | $59,681 | Research payment | Cash or cash equivalent | LEQVIO Drug, CARDIOVASCULAR | A RANDOMIZED, MULTICENTER, OPEN-LABEL TRIAL COMPARING THE EFFECTIVENESS OF AN INCLISIRAN FIRST IMPLEMENTATION STRATEGY T | 2022 |
| 2022-02-23 | Gilead Sciences, Inc. | $1,202 | Research payment | Cash or cash equivalent | | A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Opt | 2022 |
| 2022-02-22 | Volta Medical Inc | $2,531 | Research payment | Cash or cash equivalent | VX1 Device, CARDIOVASCULAR | Tailored AF | 2022 |
| 2022-02-10 | Novartis Pharmaceuticals Corporation | $266 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | A MULTICENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP ACTIVE CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LCZ6 | 2022 |
| 2022-01-14 | Novartis Pharmaceuticals Corporation | $459 | Research payment | Cash or cash equivalent | ENTRESTO Drug, CARDIOVASCULAR | PROSPECTIVE COMPARISON OF ANGIOTENSIN RECEPTOR NEPRILYSIN INHIBITOR ARNI VERSUS ACE INHIBITOR TRIAL TO DETERMINE IMPACT | 2022 |
| 2022-01-13 | Boston Scientific Corporation | $110 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CRM | LONGEVITY STUDY | 2022 |
| 2022-01-11 | BIOTRONIK INC. | $1,200 | Consulting Fee | Cash or cash equivalent | Edora 8 DR-T Device, Cardiology/Vascular Diseases | | 2022 |
| 2022-01-04 | Boston Scientific Corporation | $818 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CRM | LUX TRENDS | 2022 |
| 2022-01-04 | Boston Scientific Corporation | $264 | Research payment | Cash or cash equivalent | CLINICAL TRIAL PRODUCT Device, CRM | LUX TRENDS | 2022 |
Comments